ID   LiSa-2
AC   CVCL_M821
SY   LISA-2
DR   cancercelllines; CVCL_M821
DR   Cosmic; 2307721
DR   Cosmic; 2800522
DR   GEO; GSE3643
DR   GEO; GSM482515
DR   Progenetix; CVCL_M821
DR   Wikidata; Q54902640
RX   PubMed=11093810;
RX   PubMed=18283285;
RX   PubMed=20197395;
RX   PubMed=22911243;
RX   PubMed=24726063;
RX   PubMed=26643872;
CC   Characteristics: Can be differentiated into mature adipocytes.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Leu348Ser (c.1043T>C); Zygosity=Unspecified (PubMed=26643872).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Retroperitoneal space; UBERON=UBERON_0003693.
DI   NCIt; C3705; Pleomorphic liposarcoma
DI   ORDO; Orphanet_99969; Pleomorphic liposarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 19-12-24; Version: 18
//
RX   PubMed=11093810; DOI=10.1002/1097-0215(20001215)88:6<889::AID-IJC8>3.0.CO;2-N;
RA   Wabitsch M., Bruderlein S., Melzner I., Braun M., Mechtersheimer G.,
RA   Moller P.;
RT   "LiSa-2, a novel human liposarcoma cell line with a high capacity for
RT   terminal adipose differentiation.";
RL   Int. J. Cancer 88:889-894(2000).
//
RX   PubMed=18283285; DOI=10.1038/ijo.2008.10;
RA   van Beek E.A., Bakker A.H.F., Kruyt P.M., Vink C., Saris W.H.M.,
RA   Franssen-van Hal N.L.W., Keijer J.;
RT   "Comparative expression analysis of isolated human adipocytes and the
RT   human adipose cell lines LiSa-2 and PAZ6.";
RL   Int. J. Obes. 32:912-921(2008).
//
RX   PubMed=20197395; DOI=10.1158/1535-7163.MCT-09-0705; PMCID=PMC2837520;
RA   Mitchell M.A., Johnson J.E., Pascarelli K., Beeharry N., Chiourea M.,
RA   Gagos S., Lev D.C., von Mehren M., Kipling D., Broccoli D.;
RT   "Doxorubicin resistance in a novel in vitro model of human pleomorphic
RT   liposarcoma associated with alternative lengthening of telomeres.";
RL   Mol. Cancer Ther. 9:682-692(2010).
//
RX   PubMed=22911243; DOI=10.1155/2012/148614; PMCID=PMC3403520;
RA   Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S.,
RA   Munthe E., Myklebost O.;
RT   "Characterization of liposarcoma cell lines for preclinical and
RT   biological studies.";
RL   Sarcoma 2012:148614.1-148614.9(2012).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33; PMCID=PMC4022359;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
//
RX   PubMed=26643872; DOI=10.18632/oncotarget.6464; PMCID=PMC4767443;
RA   Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K.,
RA   Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U.,
RA   Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K.,
RA   Tanaka H., Miyano S., Myklebost O., Yang H.H., Dugas M.,
RA   Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S.,
RA   Koeffler H.P.;
RT   "Genomic landscape of liposarcoma.";
RL   Oncotarget 6:42429-42444(2015).
//